Avenir Corporation’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$318K Hold
1,462
0.04% 58
2025
Q4
$334K Hold
1,462
0.04% 60
2025
Q3
$339K Hold
1,462
0.04% 59
2025
Q2
$271K Hold
1,462
0.03% 65
2025
Q1
$306K Hold
1,462
0.03% 57
2024
Q4
$260K Hold
1,462
0.03% 60
2024
Q3
$289K Hold
1,462
0.03% 58
2024
Q2
$251K Hold
1,462
0.02% 62
2024
Q1
$266K Hold
1,462
0.02% 61
2023
Q4
$227K Hold
1,462
0.02% 60
2023
Q3
$218K Buy
+1,462
New +$215K 0.02% 57
2023
Q2
Sell
-1,462
Closed -$233K 61
2023
Q1
$233K Hold
1,462
0.02% 59
2022
Q4
$236K Buy
+1,462
New +$224K 0.02% 58
2022
Q3
Sell
-1,462
Closed -$224K 61
2022
Q2
$224K Hold
1,462
0.02% 58
2022
Q1
$237K Buy
+1,462
New +$212K 0.02% 61

Other funds holding ABBV

Avenir Corporation's ABBV Position: Q1 2026 in Review

Avenir Corporation held its AbbVie (ABBV) position steady in Q1 2026 at 1,462 shares worth $318K. The position accounts for 0.04% of the portfolio, ranked #58.

Avenir Corporation first reported a position in ABBV in Q1 2022 and has held it in 15 quarters since. The position peaked at $339K in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Avenir Corporation held 1,462 shares of AbbVie worth $318K as of Q1 2026.
  • Avenir Corporation left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.04% of Avenir Corporation's portfolio in Q1 2026, its #58 holding.
  • Avenir Corporation first reported a position in AbbVie in Q1 2022 and has held it in 15 quarters since.
  • Avenir Corporation's AbbVie position peaked at $339K in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Avenir Corporation's 13F filing for Q1 2026, filed 14 May 2026.